Evaluation of the safety and efficacy of combined treatment with anti-CD19 and anti-BCMA CAR-T cells in participants with relapsed or refractory MM have indicated that administration of humanized CD19-CAR-T cells accompanied by murine BCMA CAR-T cells at the similar dosage of 1 × 106 cells/kg following lymphocyte depletion may result in significant preliminary activity. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.